{"organizations": [], "uuid": "6c52f2f219c22c5708d6ff1834bb0ffe5847ac80", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/09/10/sun-pharm-divestiture-ireland-idUSL4N11F50Q20150910", "country": "US", "title": "REFILE-India's Sun Pharma looking to divest Ireland plant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "REFILE-India's Sun Pharma looking to divest Ireland plant | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-09-10T06:17:00.000+03:00", "replies_count": 0, "uuid": "6c52f2f219c22c5708d6ff1834bb0ffe5847ac80"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/09/10/sun-pharm-divestiture-ireland-idUSL4N11F50Q20150910", "ord_in_thread": 0, "title": "REFILE-India's Sun Pharma looking to divest Ireland plant", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "(Corrects date in dateline)\nMUMBAI, Sept 10 (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories Ltd.\nThe world's fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.\n\"Decisions are being made to either close or divest some of our manufacturing facilities,\" a Sun Pharma spokesman said in an emailed statement.\n\"Currently, the Ireland facility has been identified for divestment.\"\nFollowing the completion of the Ranbaxy acquisition in March this year, Sun Pharma last month reported one-off integration-related costs of 6.85 billion rupees ($102.86 million) for the quarter ended June.\nIt has warned that revenue may remain flat or decline this fiscal year, as it faces supply constraints at one of its own plants in the western Indian state of Gujarat. ($1 = 66.5945 Indian rupees) (Reporting by Zeba Siddiqui in Mumbai; Editing by Subhranshu Sahu)", "external_links": [], "published": "2015-09-10T06:17:00.000+03:00", "crawled": "2015-09-10T05:21:13.888+03:00", "highlightTitle": ""}